

Rubella virus tropism and single cell responses in human primary tissue and microglia-containing organoids

Reviewed Preprint

Published from the original preprint after peer review and assessment by eLife.

About eLife's process

Reviewed preprint version 2

June 22, 2023

Reviewed preprint version 1

May 23, 2023 (this version)

Sent for peer review

March 31, 2023

Posted to preprint server

October 24, 2022

Galina Popova, Hanna Retallack, Chang N. Kim, David Shin, Albert Wang, Joseph DeRisi ,
Tomasz J. Nowakowski 

Department of Anatomy, University of California San Francisco, San Francisco, CA, USA • Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA • Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of California, San Francisco, CA, USA • Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA • Chan Zuckerberg Biohub, San Francisco, CA, USA • Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

Rubella virus is an important human pathogen that can cause neurologic deficits in a developing fetus when contracted during pregnancy. Despite successful vaccination programs in the Americas and many developed countries, rubella remains endemic in many regions worldwide and outbreaks occur wherever population immunity is insufficient. Intense interest since rubella virus was first isolated in 1962 has advanced our understanding of clinical outcomes after infection disrupts key processes of fetal neurodevelopment. Yet it is still largely unknown which cell types in the developing brain are targeted. We show that in human brain slices, rubella virus predominantly infects microglia. This infection occurs in a heterogeneous population but not in a highly microglia-enriched monoculture in the absence of other cell types. By using an organoid-microglia model, we further demonstrate that rubella virus infection leads to a profound interferon response in non-microglial cells, including neurons and neural progenitor cells, and this response is attenuated by the presence of microglia.

eLife assessment

The manuscript represents an **important** study on the pathogenesis of rubella virus tropism and neuropathology in human microglia-containing human stem cell derived organoids and human fetal brain slices. The strength of evidence is **compelling**, using state-of-the-art multimodal technologies. The findings will be of interest to neuroscientists, virologists, and epidemiologists, presenting novel hypotheses and generally helpful tools.

Introduction

Neurotropic viruses contracted during pregnancy can have grave consequences for the fetus. These comprise both viruses of longstanding concern like Human cytomegalovirus and Herpes simplex virus as well as emerging viruses like Zika virus. Yet our understanding of how direct viral infection and indirect inflammatory consequences affect fetal brain development is limited. This is true even for well-studied pathogens like rubella virus (RV), which is an enveloped, single-stranded RNA virus of the family *Matonaviridae* restricted to human transmission. Infection with RV typically causes a mild, self-limiting illness with a characteristic rash during childhood, often referred to as “German measles.” However, infection during pregnancy can cause miscarriage, stillbirth, or a range of birth defects including congenital rubella syndrome (CRS). The sequelae of congenital RV infection were first recognized in 1941 and although the first RV vaccines were licensed in 1969, an estimated 105,000 infants with CRS were born each year worldwide as of 2010 (Vynnycky et al., 2016 [↗](#)). As of 2019, RV-containing vaccine coverage remains incomplete and inconsistent, with ongoing endemic transmission and reporting gaps primarily in the African, Eastern Mediterranean, and South-East Asian World Health Organization Regions (World Health Organization, 2020). Countries with RV-containing vaccine programs also remain susceptible to outbreaks, such as Japan and China where outbreaks in 2013-14 and 2018-19 caused a two-fold increase in reported rubella cases worldwide (26,033 total cases in 2018 vs 49,179 cases in 2019) (Plotkin, 2021 [↗](#)) and included CRS the following year (423 total cases worldwide in 2019 vs 1,252 cases in 2020) (World Health Organization, 2022).

The most common features of CRS are congenital cataracts, sensorineural deafness, and cardiac defects (Banatvala & Brown, 2004 [↗](#)). In addition, microcephaly (Munro, Sheppard, Smithells, Holzel, & Jones, 1987 [↗](#)), developmental delay and autism (Chess, 1977 [↗](#)), and schizophrenia spectrum disorders (Brown et al., 2001 [↗](#)) are associated with the syndrome, but the pathophysiology of these neurological complications is not well described. To gain mechanistic insight into the pathophysiology of CRS it is essential to understand the tropism of the virus. Initial infection in the lymphoid tissues of the nasopharynx and upper respiratory tract leads to systemic viremia, with virus spread across the placenta and into nearly all fetal organs on post-mortem examination, primarily via infected mononuclear cells (Nguyen, Pham, & Abe, 2015 [↗](#)). As for the fetal nervous system, RV was isolated from cerebrospinal fluid and brain tissue of fetuses and infants with CRS in studies from the 1960s (Bellanti et al., 1965 [↗](#); Esterly & Oppenheimer, 1967 [↗](#); Korones, 1965 [↗](#); Monif, Avery, Korones, & Sever, 1965 [↗](#)). However, further details of where RV might replicate in the brain are lacking. Autopsies in that early era revealed nonspecific gliosis and cerebral vessel degeneration (Rorke & Spiro, 1967 [↗](#)). In limited pathology specimens from more recent outbreaks, RV RNA and antigens were identified in rare cells in the cortex and cerebellum presumed to be “nerve cells” and neural progenitor cells (Lazar et al., 2016 [↗](#); Nguyen et al., 2015 [↗](#)). Experimental infections of cells that might not accurately represent the primary cells in the developing brain have yielded little further insight. To complicate the matter, myelin oligodendrocyte glycoprotein (MOG) has been proposed as a cellular receptor for RV (Cong, Jiang, & Tien, 2011 [↗](#)), but it is exclusively expressed in oligodendrocytes in the human brain and therefore cannot explain infection in other cell populations. Thus, there is clear evidence for the presence of RV in the central nervous system in infants with CRS, but the identity of infected cell type(s) remains elusive.

Here we address RV tropism in the human developing brain and other poorly understood molecular aspects of CRS. By combining primary human brain tissue with a variety of cell culture techniques, we show that microglia are the predominant cell type infected by RV. Furthermore, we show that diffusible factors from non-microglia cells are necessary to render microglia susceptible to RV. By using brain organoids supplemented with primary microglia, we demonstrate that RV infection leads to a robust interferon response and leads to dysregulation of multiple genes

implicated in human brain development. Finally, we compared transcriptomic changes between microglia-transplanted and non-transplanted organoids and found that in the presence of microglia, interferon pathway upregulation following RV exposure is reduced.

Results

RV infects microglia in the human developing brain

To investigate RV tropism in the human brain, cultured cortical slices from mid-gestation samples were infected with M33 RV, representing a laboratory strain originally derived from a clinical isolate (**Figure 1A** [↗](#)). At 72 hours post-infection, immunostaining for the RV capsid protein revealed numerous cells positive for the RV antigen, of which >90% were co-labeled with the microglia marker Iba1 (**Figure 1B-D** [↗](#)). To confirm functional transcription and translation of the viral genome, a new strain of RV designed to express GFP within the non-structural P150 gene was generated (RV-GFP, GenBank Accession OM816675, **Figure 1E** [↗](#)) and validated by GFP expression in Vero cells (Supplementary Figure 1). In human primary brain slices infected with RV-GFP, GFP expression was detected predominantly in microglia, confirming the production of RV proteins inside this cell type (**Figure 1F** [↗](#)) consistent with the wildtype M33 RV.

Cell microenvironment influences RV infectivity

Such specificity of RV for microglia in this model is striking given that microglia represent only 1-5% of the cells of the human developing brain (D.A. Menassa et al., 2021 [↗](#)). Moreover, the previously published viral entry factor MOG is not specific to microglia according to analysis of publicly available RNA and protein expression profiles of the human developing brain (Supplementary Figure 2). Further, common components of the host cell membrane, such as sphingomyelin and cholesterol that appear to be essential for RV entry (Otsuki et al., 2018 [↗](#)), cannot explain viral tropism for microglia. Thus, to identify factors contributing to the relatively specific infection of microglia, RV infectivity was tested in monocultures of primary human microglia. Microglia from mid-gestation cortical brain samples were purified using magnetic-activated cell sorting (MACS) and then subsequently infected with RV (**Figure 2A** [↗](#)). Surprisingly, RV infection of the microglia monoculture was negligible (**Figure 2B** [↗](#)). To resolve this apparent paradox, we investigated whether microglia infectivity could be restored by the presence of other cell types, such as neurons or progenitor cells. Microglia were co-cultured with either neuronally-enriched cultures (sorted with PSA-NCAM magnetic beads), or the glial component (flow-through that was depleted of both the CD11b-positive microglia cells and the PSA-NCAM-positive population). Both conditions successfully restored infection (**Figure 2C-E** [↗](#)). In the pure microglial cultures, less than 2% of microglia were positive for RV capsid by immunostaining, but when different cell fractions were added to the culture (neuronal; glial; or mixed cultures), up to 60% of microglia had RV capsid immunopositivity (**Figure 2F** [↗](#)). Similar to the cortical brain slices, microglia represented the main cell type infected with RV in the mixed co-cultures (**Figure 2G** [↗](#)). Furthermore, mixed cultures inoculated with lower viral titers had fewer cells with RV capsid immunopositivity overall, but retained a high proportion of infected microglia demonstrating specificity for microglia (Supplementary Figure 3).

We then tested whether RV capsid immunopositivity in microglia could be due to phagocytic activity by this macrophage population. To exclude microglia engulfing other infected cells, a transwell system was employed where microglia and other cell types are grown in compartments separated by a semi-permeable membrane that allows media exchange without direct cell-cell contacts (**Figure 3A** [↗](#)). Both the presence of other cell types in the same well (co-culture) and the media exchange between the two chambers (transwell) restored infection in microglia (**Figure 3B-**




Figure 1.

Rubella virus infects primary human microglia in cultured brain slices.

A. Schematic for brain slice infection. Mid-gestation (GW18-23) human brain slices were infected with RV for 72 hours. **B,C.** Immunostaining for RV capsid and Iba1 on cultured cortical slices at 72 hpi, at 10x with scale bar 100 μ m (**B**) and at 40x objective with scale bar 50 μ m (**C**). **D.** Quantification of RV capsid-positive cells co-labeled with microglial marker Iba1: 764/819 (93.3%) of RV+ cells were microglia based on Iba1 staining across four biological replicates. Error bars denote standard deviation. **E.** Diagram of viral genome of GFP-expressing RV (RV-GFP). Cortical brain slices were infected with RV-GFP for 72 hours. **F.** Examples of GFP fluorescence and Iba1 immunostaining at 72 hpi of cultured cortical slices with RV-GFP, at 62x with scale bar 20 μ m. GFP expression of modified rubella virus is localized to Iba1-positive microglia cells (arrows).




Figure 2.

Rubella infection of microglia is dependent on the presence of other cells.

A. Schematic of rubella infection. Primary prenatal brain tissue was dissociated and different cell types were purified using MACS. Microglia cells were cultured alone or in combination with neurons, glial cells, or all cell types. 2D cultures were infected with RV for 72 hours and processed for immunostaining. **B-E.** Representative images of microglia cultured with different cell types. Cell cultures were stained for microglia marker Iba1 (red), RV capsid (green) and DAPI (grey; on the overlay Merge channel). **B.** Purified microglia only. **C.** Microglia and neurons co-cultured at 1:5 ratio. **D.** Microglia and non-neuronal cell types cultured together at 1:5 ratio. **E.** Microglia cultured with non-microglial cells (flow-through from a MACS purification) at 1:5 ratio. **F.** Quantification of RV capsid immunopositivity among microglia (Iba1+) for conditions in B-E. FT: flow through after microglia MACS purification. Error bars denote SEM. Each data point represents a field of view from the same experimental batch. **G.** Quantification of microglia (Iba1+) among RV capsid-positive cells.

C). Consistent with our previous experiments, microglia represented the main cell type infected with RV. Together, these results suggest that RV infection of microglia is influenced by diffusible factors from other cell populations found in the tissue microenvironment.

Rubella infection elicits an interferon response in brain organoids

Given the striking difference in infection rates in different cell environments, we next investigated how the presence of microglia modulates gene expression profiles associated with the presence of RV. Under standard protocols, brain organoids do not robustly develop any cells of myeloid origin, making them a useful reductionist model for investigating the role of immune cells in brain homeostasis and development. Brain organoids were generated following previously established protocols (Pasca et al., 2015), and at five weeks of differentiation, when the majority of cell types are present in the organoids, mid-gestation primary human microglia were introduced as previously described (Popova et al., 2021). After allowing microglia to engraft into the organoids for five weeks, organoids were infected with RV. At 72 hours post-infection with RV, brain organoids were processed for single-cell RNA sequencing with 10X Genomics and downstream analysis (Figure 4A). In organoids with engrafted primary microglia subsequently exposed to RV, immunostaining revealed RV capsid in microglia, similar to primary tissue and co-culture experiments (Figure 4B). After processing for single-cell RNA sequencing, cells with fewer than 500 detected genes and/or more than 20% mitochondrial genes were removed from the analysis. Ribosomal transcripts and pseudogenes were excluded. Approximately 11,000 cells passed filtering criteria, revealing the expected major cell populations of the human developing brain (Nowakowski et al., 2017), including radial glia cells, immature and mature neurons, and astrocytes (Figure 4C, D). Cell cluster annotations were assigned based on combinations of co-expressed cluster marker genes, such as *FGFBP2* and *SOX2* for radial glial cells (clusters 5 and 10), *TAGLN3*, *HES6*, *NEUROD4* for neural progenitor cells (cluster 7), *TUBB2A*, *TUBB2B*, *STMN2* for neurons (cluster 2), *CLU*, *PTN* and *SPARCL1* for astrocytes (cluster 6), and *MKI67*, *UBE2C* and *CENPF* for dividing cells (clusters 3 and 4) (Figure 4C, Supplementary Figure 4 D-E for individual cluster marker genes, Table 1 for the full list of markers). Cells derived from organoids with and without microglia were present in all clusters (Figure 4E). A separate microglia cluster was not identified. Rare cells expressing the microglia marker *AIF1* (encoding the Iba1 protein) were present, but such cells have been previously reported to develop spontaneously in organoids (He et al., 2022) and the canonical microglia marker *P2RY12* was not detected in those cells (Supplementary Figure 4F). We attribute the apparent lack of microglia to both the small starting population and loss due to cell dissociation during processing for scRNAseq. Consistent with the lack of microglia cells in our scRNAseq data, we did not recover appreciable numbers of the viral transcripts. However, exposure of organoids to RV resulted in significant transcriptomic differences including genes involved in the interferon signaling pathway and its response (*IFI27*, *IFI6*, *IFITM3*)(*HLA-A* (Campbell, Bizilj, Colman, Tuch, & Harrison, 1986; Keskinen, Ronni, Matikainen, Lehtonen, & Julkunen, 1997) and *BST2* (Holmgren, Miller, Cavanaugh, & Rall, 2015)) (cluster 1, Figure 4C,D,F, Table 1). The majority of cells in cluster 1 came from RV-exposed organoids. While genes involved in the interferon response showed increased expression in organoids both with and without microglia, the magnitude of their upregulation was lower among cells in microglia-containing organoids (Figure 4E-F).

Radial glia and dividing cells had a greater transcriptomic response to RV exposure as compared to neurons, both with and without microglia (Figure 4G). Cells captured from microglia-containing organoids showed fewer differentially expressed genes in response to RV in each of the major cell classes compared to organoids that did not contain microglia (Figure 4G), with radial glia and neurons reaching statistically significant levels (p-values shown on the right side of the panel) and neural progenitor cells showing the overall trend without reaching statistical significance. One gene family that was specifically upregulated in the presence of RV in organoids without microglia included nuclear factor I – *NFIB* and *NFIA* (Figure 4G, Table 2) – two genes that form heterodimers *in vivo* and are associated with induction of gliogenesis (Tchieu et al.,




Figure 3.

Direct cell-cell contact is not required for microglia infection by rubella.

A. Schematic for experimental set up. Primary human brain tissue was dissociated, and microglia were cultured with or without microglia-depleted flow through portion. Cells were co-cultured in direct contact or in solution-permeable chambered transwells (TW). **B.** Representative images of microglia-enriched cultures (top row), microglia cultured with other cell types in the same well (middle row), and microglia cultured in the bottom compartment with other cell types cultured in a permeable transwell chamber (bottom row) infected with RV for 72 hours. **C.** Quantification of RV capsid immunopositivity among microglia (Iba1+). Three fields of view across the same experiment were quantified for each condition. Error bars represent SEM. p-value between microglia and co-culture condition is 0.0479. p-value between microglia and trans well condition is 0.0159. **D.** Quantification of microglia (Iba1+) among RV capsid-positive cells.




Figure 4.

Rubella infects microglia in brain organoids and leads to interferon response.

A. Primary human microglia were transplanted into brain organoids, resulting neuro-immune organoids were infected with RV and 72 hours post-infection were processed for downstream analysis. **B.** Immunofluorescence imaging of brain organoids including markers of radial glial cells (Sox2), transplanted microglia (Iba1) and RV capsid (RV). **C.** Single cell RNA sequencing analysis identified 13 clusters, including neurons and glial cells (Div.: dividing cells, RG: radial glia, Astros: astrocytes). **D.** Dot plot depicting cluster marker genes for each cluster. **E.** UMAP plots of organoids colored by condition. Left: organoids with or without microglia. Right: organoids that were infected with RV or controls. **F.** Feature plot (left) and violin plot (right) for Interferon Alpha Inducible Protein 6 (IFI6) across different conditions. **G.** Differentially expressed genes in different cell types in response to RV infection without (top panel) and with microglia (bottom panel). In the presence of microglia, fewer differentially expressed genes in response to RV infection were identified across all major cell types. Kolmogorov-Smirnov test was used on DEGs with $p\text{-value} < 0.05$. *** < 0.001 , NS – not significant, * < 0.05 . **H.** Violin plots for select genes differentially expressed in response to RV and presence of microglia.

2019) in embryonic brain development. Early disruption in the function of either gene is associated with neurodevelopmental deficits and perinatal mortality in mice (das Neves et al., 1999; Steele-Perkins et al., 2005) and with intellectual disability in humans (Schanze et al., 2018).

Genes with expression levels affected both by the presence of microglia and by RV exposure included NOVA alternative splicing regulator 1 (*NOVA1*) and Ribonuclease K (*RNASEK*) (Figure 4H). *RNASEK* was specifically expressed in organoids transplanted with microglia only after exposure to RV, and is required for infection by a variety of viruses that enter cells via the endosome (Hackett et al., 2015).

Discussion

Here we demonstrate that in the developing brain RV predominantly infects microglia, the resident macrophage population. This finding is consistent with RV tropism for monocytes in the periphery (Perelygina et al., 2021; van der Logt, van Loon, & van der Veen, 1980), and adds new information to the limited understanding of RV infection in the central nervous system. Supporting data from real-world infections including post-mortem specimens would be helpful to evaluate clinical strains. Tropism for microglia raises interesting questions about how and where RV persists in CRS, perhaps in brain tissue during the extended period of viral shedding, similar to other relatively immuno-privileged sites such as the eye (Doan et al., 2016; Sugishita et al., 2016). Our findings also help contextualize CRS in comparison to congenital infections by other neurotropic viruses: Human immunodeficiency virus type 1 and Zika virus, which target microglia directly; Herpes simplex virus, which replicates poorly in microglia with cytopathic effect; and Human cytomegalovirus, which causes microglia to produce antiviral cytokines without productive infection or cytopathic effect (Lum et al., 2017; Retallack et al., 2016; Rock et al., 2004).

Like some of these other viruses, we found that by establishing viral transcription and translation in microglia, RV elicits a strong interferon response in other cell types. It has been previously shown that the interferon response in neurons derived from induced pluripotent stem cells can induce molecular and morphological changes associated with neurodevelopmental disorders, including neurite length and gene expression changes associated with schizophrenia and autism (Warre-Cornish et al., 2020). The interferon response is additionally associated with pathobiology in a range of congenital infections and interferonopathies (Crow & Manel, 2015). Furthermore, in our preliminary experiments in organoids, where microglia do not develop under standard protocols, the RV-induced interferon response was attenuated in the presence of microglia, suggesting a possible protective role of microglia on other cell types. One limitation of the current work is the lack of information on transcriptional differences in microglia in the context of RV-exposed organoids due to the low number of recovered microglia. However, our data on molecular changes in neural progenitor cells and neurons, which likely produce the bulk of neurological symptoms seen in CRS, provide a valuable resource for future investigation of congenital viral infections. Our finding that the presence of microglia may reduce RV-associated transcriptional differences across different cell populations may also shed light on neuro-immune consequences of other congenital infections that coincide temporally with phases of microglia population expansion and reduction (D. A. Menassa et al., 2022).

Interestingly, RV infection rates were largely influenced by the local cell environment, where diffusible factors from non-microglia cells were necessary for RV infection of microglia. These factors did not depend on the cell type, as both progenitor/glia cells and neurons were equally effective in supporting RV infection of microglia. This finding opens new directions to advance our limited understanding of host factors needed for RV entry and infection. Based on previous reports in 2D cell cultures and pathology examination of infected tissues, RV can establish

infection in a variety of cell types, suggesting that the viral entry receptor is ubiquitously expressed, or that viral entry is facilitated by cell membrane components and their modifications. Indeed, membrane phospholipids and glycolipids have been shown to participate in viral entry (Mastromarino, Cioe, Rieti, & Orsi, 1990 [DOI](#); Otsuki et al., 2018 [DOI](#)). Our study suggests secreted factors may also contribute to RV entry, perhaps in conjunction with other ubiquitous cell surface elements.

Moreover, our study highlights the importance of considering tissue complexity when studying viral infection in brain organoids. Complex, multi-lineage organoids can now be designed by incorporating vascular or immune cells into differentiation protocols (Cakir et al., 2022 [DOI](#); Cakir et al., 2019 [DOI](#); Popova et al., 2021 [DOI](#)). We show that transcriptomic consequences of RV exposure are dependent on the presence of microglia in the organoid tissue environment. Future studies will be needed to determine the precise mechanisms that mediate this effect. One possibility is that microglia become the predominant cellular target of RV infection. Another possibility is microglia actively altering the microenvironment to modulate the antiviral response.

Clearly, efforts to eliminate RV worldwide through vaccination are a priority. However, our work on neuro-immune interactions in CRS may inform how early brain development goes awry in many contexts including prenatal infection with other neurotropic viruses, genetic conditions associated with dysregulated interferon responses such as Aicardi Goutières Syndrome, and a variety of perturbations that activate common inflammatory pathways. Understanding the specific role of microglia may be key to unlocking the pathophysiology and developing therapies to prevent or mitigate damage.

Data availability

Sequences of RV and RV-GFP have been deposited at Genbank under accessions OM816674 and OM816675 respectively. Single-cell RNA-seq data for iPSC-derived organoids will be deposited at GEO and will be made publicly available as of the date of publication. Processed single-cell data, including dimensionality reduction object, is freely available at rubella-organoids.cells.ucsc.edu.

Acknowledgements

We thank Tom Hobman for generously sharing reagents for the Rubella M33 strain, and all members of the Nowakowski and DeRisi laboratories for helpful discussions and comments throughout this project. We would like to thank UCSC Cell Browser and especially Maximilian Haeussler and Brittney Wick for making the single cell data publicly available. This study was supported in part by gifts from Schmidt Futures and the William K. Bowes Jr. Foundation, Simons Foundation grant (SFARI 491371 to T.J.N.), Chan Zuckerberg Biohub Intercampus Investigator Award, NARSAD Young Investigator Grant (to T.J.N.), and NRSA F32 1F32MH118785 (to G.P.), NINDS F31NS108615 (to H.R.), UCSF Discovery Fellows Program (to H.R.), and the Chan Zuckerberg Biohub (to J.D.).

Author contributions

These authors contributed equally: G.P., H.R..

G.P. and H.R. performed the experiments and analyzed the data. C.N.K. analyzed single cell RNA sequencing data. D.S. provided brain organoids and A.W. performed immunofluorescence. G.P. and H.R. prepared figures and wrote the manuscript with input from all authors. T.J.N. and J.D. provided oversight of the project. All authors reviewed the manuscript and agreed on its content.

Materials and Methods

Cell lines

Vero cells were obtained from ATCC (CRL-1587) and maintained in DMEM (ThermoFisher, 11965-118) with 10% (vol/vol) fetal bovine serum (ThermoFisher, 10438026), 10mM HEPES (ThermoFisher, 15630-080), and 1X penicillin/streptomycin (ThermoFisher, 10378016). Cell cultures were routinely checked to be free from mycoplasma.

Rubella Virus

To generate viral stocks, a plasmid containing a full infectious clone of RV-M33 was linearized then added to an *in vitro* transcription reaction with Sp6 (New England Biolabs, M0207L). The resulting RNA was purified then polyadenylated (New England Biolabs, M0276S) and capped using Vaccinia Capping System (New England Biolabs, M2080S). This RNA was then introduced to Vero cells using TransIT-mRNA transfection (Mirus Bio, MIR 2250). At 72 hours post-transfection, culture media was collected and passaged onto fresh Vero cells. To generate viral stocks, Vero cells were inoculated with low passage number RV (P2-P3) and cultured at 37°C. Culture media was collected at 72 hours post-inoculation, clarified, and stored at -80°C. Immunofluorescent titering assays were performed on Vero cells using anti-RV capsid antibody (ab34749), yielding titers of 10^5 - 10^6 focus-forming units/mL (ffu/mL) for RV stocks. RV-GFP stocks were prepared in the same manner, from a plasmid that had been modified through an *in vitro* reaction with nCas9 and custom guides to cut the RV-M33 plasmid midway through the p150 gene at residues 717-718 (dgrRNA system with DNA oligos for RNA *in vitro* transcription as follows: tracrRNA sequence: AAA AAG CAC CGA CTC GGT GCC ACT TTT TCA AGT TGA TAA CGG ACT AGC CTT ATT TTA ACT TGC TAT GCT GTC CTA TAG TGA GTC GTA TTA, crRNA oRV012 sequence: CAA AAC AGC ATA GCT CTA AAA CGC TCG CGG CCA CGT CAC CGC CTA TAG TGA GTC GTA TTA). After cutting the plasmid, an sfGFP sequence flanked by Gly-Gly-Ser-Gly-Gly linkers (PCR-amplified using primers oRV010: CTG GCC CCG GCC AGC TCG GAG GAT CGG GCG GAA TGA GCA AGG GCG AGG AG and oRV011: GTG ACG TGG CCG CGA GTC CTC CTG ATC CGC CAG TGA TCC CGG CGG CG) was inserted using InFusion (TakaraBio, 638916). GFP expression of the resulting virus was validated through co-labeling of RV-GFP infected Vero cells with anti-RV capsid antibody. All viral stocks were tested to be free from mycoplasma.

Consent statement UCSF

De-identified tissue samples were collected with previous patient consent in strict observance of the legal and institutional ethical regulations. Protocols related to human iPSC cells were approved by the Human Gamete, Embryo, and Stem Cell Research Committee (institutional review board) at the University of California, San Francisco.

Primary prenatal brain slices

Deidentified primary tissue samples were collected with previous patient consent in strict observance of the legal and institutional ethical regulations. Cortical brain tissue was immediately placed in a sterile conical tube filled with oxygenated artificial cerebrospinal fluid (aCSF) containing 125 mM NaCl, 2.5 mM KCl, 1mM MgCl₂, 1 mM CaCl₂, and 1.25 mM NaH₂PO₄ bubbled with carbogen (95% O₂/5% CO₂). Blood vessels and meninges were removed from the cortical tissue, and then the tissue block was embedded in 3.5% low-melting-point agarose (Thermo Fisher, BP165-25) and sectioned perpendicular to the ventricle to 300 μm using a Leica VT1200S vibrating blade microtome in a sucrose protective aCSF containing 185 mM sucrose, 2.5 mM KCl, 1 mM MgCl₂, 2 mM CaCl₂, 1.25 mM NaH₂PO₄, 25 mM NaHCO₃, 25 mM d-(+)-glucose. Slices were transferred to slice culture inserts (Millicell, PICM03050) on six-well culture plates (Corning) and cultured in prenatal brain slice culture medium containing 66% (vol/vol) Eagle's basal medium,

25% (vol/vol) HBSS, 2% (vol/vol) B27, 1% N2 supplement, 1% penicillin/streptomycin and GlutaMax (Thermo Fisher). Slices were cultured in a 37 °C incubator at 5% CO₂, 8% O₂ at the air-liquid interface created by the cell culture insert.

Primary human microglia purification

Deidentified primary tissue samples were collected with previous patient consent in strict observance of the legal and institutional ethical regulations. Brain tissue was immediately placed in a sterile conical tube filled with oxygenated artificial spinal fluid (aSCF) containing 125 mM NaCl, 2.5 mM KCl, 1mM MgCl₂, 1 mM CaCl₂, and 1.25 mM NaH₂PO₄ bubbled with carbogen (95% O₂/5% CO₂). Prenatal human microglia were purified from primary brain tissue from mid-gestation (gestational week 18-23) samples using magnetic-activated cell sorting (MACS) kit with CD11b magnetic beads (Miltenyi Biotec, 130-049-601) following manufacturer's instructions. Briefly, primary brain tissue was minced to 1mm³ pieces and enzymatically digested in 10 ml of 0.25% trypsin reconstituted from 2.5% trypsin (Gibco, 15090046) in DPBS (Gibco, 14190250) for 30 mins at 37 °C. 0.5 ml of 10 mg/ml of Dnase (Sigma Aldrich, DN25) was added in the last 5 minutes of dissociation. After the enzymatic digestion, tissue was mechanically triturated using a 10 ml pipette, filtered through a 40 µm cell strainer (Corning 352340), pelleted at 300xg for 5 minutes and washed twice with DBPS. Dissociated cells were resuspended in MACS buffer (DPBS with 1 mM EGTA and 0.5% BSA) with addition of 0.5 mg/ml DNase and incubated with CD11b antibody for 15 minutes on ice. After the incubation, cells were washed with 10 ml of MACS buffer and loaded on LS columns (Miltenyi Biotec, 130-042-401) on the magnetic stand. Cells were washed 3 times with 3 ml of MACS buffer, then the column was removed from the magnetic field and microglia cells were eluted in 5 ml of MACS buffer. Cells were pelleted at 300xg, re-suspended in 1 ml of culture media, counted, and used for downstream analysis. We routinely obtained 1×10⁶ of microglia cells from a single MACS purification.

For experiments requiring microglia co-culture with different cell types, the flow through eluent from microglia selection served either as a cell type fraction depleted of microglia (denoted as “flow through”) or was used for an additional separation between neuronal and glial fractions by using PSA-NCAM antibody (Miltenyi Biotec, 130-092-966) following the same procedure described for microglia purification.

2D microglia cultures

Microglia were cultured on glass-bottom 24 well plates (Cellvis, P24-1.5H-N) pre-coated with 0.1 mg/ml of poly-d-lysine (Sigma Aldrich, P7280) for 1 hr and 1:200 laminin (Thermo Fisher, 23017015) and 1:1,000 fibronectin (Corning, 354008) for 2 hrs. Microglia were plated at 1×10⁵ cells/well and maintained in culture media containing 66% (vol/vol) Eagle's basal medium, 25% (vol/vol) HBSS, 2% (vol/vol) B27 (Thermo Fisher, 17504001), 1% N2 supplement (Thermo Fisher, 17502001), 1% penicillin/streptomycin, and GlutaMax (Thermo Fisher) additionally supplemented with 100 ng/ml IL34 (Peprotech, 200-34), 2 ng/ml TGFβ₂ (Peprotech, 100-35B), and 1x CD lipid concentrate (Thermo Fisher, 11905031) for 5-8 days. For co-culture experiments, other cell types were cultured with microglia at 5:1 ratio (1×10⁵ microglia cells for each 5×10⁵ non-microglial cells).

Organoid generation

Cerebral organoids were generated based on a previously published method (Pasca et al., 2015 [DOI](#)) with several modifications. Briefly, hiPSCs cultured on Matrigel were dissociated into clumps using 0.5 mM EDTA in Ca²⁺/Mg²⁺-free DPBS and transferred into ultra-low attachment 6-well plates in neural induction media (GMEM containing 20% (v/v) KSR, 1% (v/v) penicillin-streptomycin, 1% (v/v) non-essential amino acids, 1% (v/v) sodium pyruvate, and 0.1mM 2-mercaptoethanol). For the first nine days, neural induction media was supplemented with the SMAD inhibitors SB431542 (5 µM) and dorsomorphin (2 µM), and the Wnt inhibitor IWR1-endo (3 µM). Additionally, the Rho

Kinase Inhibitor Y-27632 (20 μ M) was added during the first four days of neural induction to promote survival. Neural induction media was replaced every two days for eight days, and Y-27632 was removed from the media on the fourth day. After neural induction, plates containing cortical organoids were transferred to a plate shaker rotating at 80 rpm. Between days 9-25, organoids were transferred to an expansion media (1:1 mixture of Neurobasal and DMEM/F12 containing 2% (v/v) B27 without vitamin A, 1% N2, 1% (v/v) non-essential amino acids, 1% (v/v) Glutamax, 1% (v/v) antibiotic/antimycotic, 0.1mM 2-mercaptoethanol) supplemented with FGF β (10 ng/mL) and EGF (10 ng/mL). Between days 25-35, organoids were maintained in neural differentiation media without FGF or EGF. From Day 35 onward, organoids were maintained in neural differentiation media containing B27 with vitamin A with full media exchanges every 2-3 days.

Microglia-organoid engraftment and co-culture

Microglia from mid-gestation cortical tissue were MACS-purified and immediately added to organoids between week 5 and 6 in 6-well plates at 1×10^5 microglia cells/organoid and kept off the shaker overnight. The following day, the plates were returned to the shaker and maintained following a usual organoid maintenance protocol.

Rubella virus infection

Cells cultured in 2D were inoculated by adding RV stock virus (see above) to culture media to achieve a multiplicity of infection (MOI) of 2. After four hours, media was exchanged with fresh cell culture media. Cortical brain slices were treated with RV viral stock applied over the slice culture filter for four hours, and then the viral culture media was removed and replaced with fresh slice culture media. Organoids were treated in 6-well plates with 2ml of 1:1 mix of RV stock:organoid maintenance media for four hours, and then viral media was exchanged for fresh media. For all experimental conditions, cells were fixed and processed for downstream analysis at 72 hours post infection. Supernatant from non-infected Vero cells (mock) or heat-inactivated RV (65°C, 30 mins) was used as control.

Immunofluorescence

Cells cultured on glass-bottom well plates were fixed in 4% PFA at the room temperature for 10 minutes and washed with PBS three times for five minutes each wash. Blocking and permeabilization were performed in a blocking solution consisting of 10% normal donkey serum, 1% Triton X-100, and 0.2% gelatin for 1 hour. Primary and secondary antibodies were diluted and incubated in the blocking solution. Cell cultures were incubated with primary antibodies at the room temperature for 1 hour, washed 3x with washing buffer (0.1% Triton X-100 in PBS), and incubated with secondary antibodies for 1 hour at the room temperature.

Organoid samples were fixed in 4% PFA at the room temperature for 1 hour. Whole organoids were incubated in 30% sucrose (w/v) at 4°C overnight, cryopreserved in OCT/30% sucrose (1:1) and then cryosectioned at 20 μ m thickness. Heat-induced antigen retrieval was performed in 10mM sodium citrate (pH=6.0) for 10 min in boiling-hot solution. After antigen retrieval, slides were washed briefly in 1x PBS. Blocking and permeabilization were performed in a blocking solution consisting of 10% normal donkey serum, 1% Triton X-100, and 0.2% gelatin for 1 hour. Primary and secondary antibodies were diluted and incubated in the blocking solution. Cryosections were incubated with primary antibodies at 4°C overnight, washed 3x for 10 minutes each with washing buffer (0.1% Triton X-100 in PBS). Slides were incubated with species-specific AlexaFluor secondary antibodies (1:2,000) overnight at 4°C and then washed with washing buffer for at least 3x for 10 minutes each. Finally, slices were mounted with glass coverslips using DAPI Fluoromount-G (Southern Biotech, 0100-20) mounting media. Cortical slices were fixed in 4% PFA at room temperature for 1 hour. Antibody staining was performed as for organoid samples above, with the exceptions that no cryosectioning or antigen retrieval was performed.

Images were collected using Leica SP8 confocal system with 20x air lens (0.75 NA) and 63x oil lens (1.40 NA). Images were processed using ImageJ/Fiji and Affinity Designer software.

Antibodies

Primary antibodies used in this study included: rabbit Iba1 (1:500, Wako, 019-19741), guinea pig Iba1 (1:500, Synaptic Systems, 234 004), mouse rubella virus capsid (1:500, Abcam, ab34749), rat Sox2 (1:500, Invitrogen, 14-9811-82), chicken GFP (1:1,000, Aves labs, GFP-1020).

Organoid single-cell capture for single-cell RNA sequencing

Two organoids per experimental condition were washed with $\text{Ca}^{2+}/\text{Mg}^{2+}$ -free DPBS and cut into 1 mm^2 pieces and enzymatically digested with papain digestion kit (Worthington, LK003163) with the addition of DNase for 1 hr at 37°C. Following enzymatic digestion, organoids were mechanically triturated using a P1000 pipette, filtered through a 40 μm cell strainer test tube (Corning 352235), pelleted at 300xg for 5 minutes, washed twice with DPBS and re-suspended in 180 μL of DPBS on ice for barcoding with MULTI-seq indices (McGinnis et al., 2019 [DOI](#)) for multiplexing. Anchor and barcoded strands unique for each sample were mixed in 1:1 molar ratio in DPBS (without BSA or FBS to avoid sequestering labeling oligonucleotides) and 20 μL of 10x Anchor:Barcode mixture was added to 180 μL of cell suspension. Cells were incubated on ice for 5 minutes, and then 20 μL of co-anchor was added to each tube. Cells were incubated on ice for additional 5 minutes and washed with ice-cold 1% BSA in DPBS. Cells were counted and kept on ice to prevent barcode loss. Two organoid lines with and without microglia that were treated with RV or uninfected Vero cell supernatant were combined and captured across seven lanes of 10x Genomics using Chromium single cell 3' reagent kit (v2 Chemistry) following the manufacturer's protocol.

Single cell RNA-seq libraries were generated using the 10x Genomics Chromium 3' Gene Expression Kit. Briefly, barcoded single cell mixtures from different conditions ranging from 2-3 individual conditions per lane were loaded onto chromium chips with a capture target of 10,000 cells per sample. The 10x protocol was modified for collection of MULTI-seq barcodes. During SPRI clean up immediately following cDNA amplification, supernatant was saved to recover the barcode fraction. Endogenous transcript cDNA remained bound to the SPRI beads and the protocol was continued for endogenous transcripts without change. Libraries were prepared following the manufacturer's protocol and sequenced on an Illumina NovaSeq with a targeted sequencing depth of 50,000 reads per cell. BCL files from sequencing were then used as inputs to the 10X Genomics Cell Ranger pipeline.

MULTI-seq barcode amplification

Supernatant collected after cDNA amplification clean up step was transferred to fresh 1.5 mL Eppendorf tubes, and 260 μL SPRI (for a final ratio of 3.2X) and 180 μL 100% isopropanol (for a final ratio of 1.8X) were added. After pipette mixing 10 times, the solution was incubated at room temperature for 5 minutes, placed on magnetic rack for solution to clear. The supernatant was removed, and the beads were washed with 500 μL of 80% ethanol twice. Air-dry beads were removed from magnet, resuspended in 50 μL buffer EB. After clearing the solution on the magnet, supernatant was transferred to a new PCR strip. Libraries were prepared with KAPA HiFi master mix with universal I5 primers and RPI primers unique for each 10x lane. PCR was performed with the following protocol: 95 °C for 5 min, (98 °C for 15 sec, 60 °C for 30 sec, 72 °C for 30 sec) repeated for 10 times, 72 °C for 1 min, 4 °C hold. PCR product was cleaned with 1.6X SPRI beads and resuspended in 25 μL buffer EB. Barcode libraries were quantified at 1:5 concentration using Bioanalyzer High Sensitivity DNA analysis. Barcodes were sequenced as fraction of endogenous cDNA library with a target of 3000-5000 barcode reads per cell.

Single cell RNA-seq analysis

CellRanger 3.0 was used to create a cell by gene matrix which was then processed using Solo (Fleming, Marioni, & Babadi, 2019 [DOI](#)) for doublet detection and removal. A minimum of 1000 genes, 500 UMI counts, and 20% mitochondrial cutoff were used to remove low quality cells from all datasets. MAST (Finak et al., 2015 [DOI](#)) was used on log normalized raw counts for all differential expression tests. The gene marker lists were filtered after testing by specifically removing unannotated genes from HGNC. Organoid demultiplexing and doublet filtering was done through deMULTiplex (McGinnis et al., 2019 [DOI](#)) (<https://github.com/chris-mcginnis-ucsf/MULTI-seq> [DOI](#)). Uniform manifold approximation and projection (UMAP) (Leland McInnes, John Healy, Nathaniel Saul, & Großberger, 2018) embeddings and neighbors for Leiden clustering (Traag, Waltman, & van Eck, 2019 [DOI](#)) were used for clustering and visualization. Nebulosa was used to generate density plots and (Bunis, Andrews, Fragiadakis, Burt, & Sirota, 2020 [DOI](#)) for color-blind friendly plotting of clusters. Pearson correlation was calculated on the intersection of the shared genes between datasets which averaged Pearson residuals for each cluster. Organoid cells were batch corrected using default parameters of the SCTransform (Hafemeister & Satija, 2019 [DOI](#)) integration workflow.

Data analysis and statistical tests

Cell co-localization with the RV capsid was quantified using the CellProfiler 3.0 software (McQuinn et al., 2018 [DOI](#)). First, individual cells were identified by using IdentifyPrimaryObjects module with threshold strategy “Global”, threshold method “Otsu” and a two-class thresholding for each individual channel for DAPI, Iba1 and RV capsid fluorescence images. Then resulting cell objects were paired by using RelateObjects module to identify Iba1-positive, RV-positive and double-positive DAPI objects. Finally, CalculateMath was used to quantify proportions for each cell population, including RV-positive and RV-negative Iba1 microglia cells and non-microglia cells, depending on the analysis.

Prism 9.3.1 was used for statistical analysis and data plotting in mixed and transwell co-cultures. Unpaired t-test with assumed Gaussian distribution of the variants and the same standard deviations were used to calculate statistical significance for any cell counts. Unpaired nonparametric Kolmogorov-Smirnov test was used to compare differentially expressed genes that reached significance value of $p=0.05$ between conditions in organoids.

References

- Banatvala J. E., Brown D. W. (2004) **Rubella** *Lancet* **363**:1127–1137 [https://doi.org/10.1016/S0140-6736\(04\)15897-2](https://doi.org/10.1016/S0140-6736(04)15897-2)
- Bellanti J. A., Artenstein M. S., Olson L. C., Buescher E. L., Luhrs C. E., Milstead K. L. (1965) **Congenital rubella. Clinicopathologic, virologic, and immunologic studies** *Am J Dis Child* **110**:464–472 <https://doi.org/10.1001/archpedi.1965.02090030484020>
- Brown A. S., Cohen P., Harkavy-Friedman J., Babulas V., Malaspina D., Gorman J. M., Susser E. S. (2001) **A.E. Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia** *Biol Psychiatry* **49**:473–486 [https://doi.org/10.1016/S0006-3223\(01\)01068-x](https://doi.org/10.1016/S0006-3223(01)01068-x)
- Bunis D. G., Andrews J., Fragiadakis G. K., Burt T. D., Sirota M. (2020) **dittoSeq: Universal User-Friendly Single-Cell and Bulk RNA Sequencing Visualization Toolkit** *Bioinformatics* <https://doi.org/10.1093/bioinformatics/btaa1011>
- Cakir B., Tanaka Y., Kiral F. R., Xiang Y., Dagliyan O., Wang J., Park I. H. (2022) **Expression of the transcription factor PU.1 induces the generation of microglia-like cells in human cortical organoids** *Nat Commun* **13** <https://doi.org/10.1038/s41467-022-28043-y>
- Cakir B., Xiang Y., Tanaka Y., Kural M. H., Parent M., Kang Y. J., Park I. H. (2019) **Engineering of human brain organoids with a functional vascular-like system** *Nat Methods* **16**:1169–1175 <https://doi.org/10.1038/s41592-019-0586-5>
- Campbell I. L., Bizilj K., Colman P. G., Tuch B. E., Harrison L. C. (1986) **Interferon-gamma induces the expression of HLA-A,B,C but not HLA-DR on human pancreatic beta-cells** *J Clin Endocrinol Metab* **62**:1101–1109 <https://doi.org/10.1210/jcem-62-6-1101>
- Chess S. (1977) **Follow-up report on autism in congenital rubella** *J Autism Child Schizophr* **7**:69–81 <https://doi.org/10.1007/BF01531116>
- Cong H., Jiang Y., Tien P. (2011) **Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus** *J Virol* **85**:11038–11047 <https://doi.org/10.1128/JVI.05398-11>
- Crow Y. J., Manel N. (2015) **Aicardi-Goutieres syndrome and the type I interferonopathies** *Nat Rev Immunol* **15**:429–440 <https://doi.org/10.1038/nri3850>
- das Neves L., Duchala C. S., Tolentino-Silva F., Haxhiu M. A., Colmenares C., Macklin W. B., Gronostajski R. M. (1999) **Disruption of the murine nuclear factor I-A gene (Nfia) results in perinatal lethality, hydrocephalus, and agenesis of the corpus callosum** *Proc Natl Acad Sci U S A* **96**:11946–11951 <https://doi.org/10.1073/pnas.96.21.11946>
- Doan T., Wilson M. R., Crawford E. D., Chow E. D., Khan L. M., Knopp K. A., DeRisi J. L. (2016) **Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens** *Genome Med* **8** <https://doi.org/10.1186/s13073-016-0344-6>
- Esterly J. R., Oppenheimer E. H. (1967) **Vascular lesions in infants with congenital rubella** *Circulation* **36**:544–554 <https://doi.org/10.1161/01.cir.36.4.544>

- Finak G., McDavid A., Yajima M., Deng J., Gersuk V., Shalek A. K., Gottardo R. (2015) **MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data** *Genome Biol* **16** <https://doi.org/10.1186/s13059-015-0844-5>
- Fleming S. J., Marioni J. C., Babadi M. (2019) **CellBender remove-background: a deep generative model for unsupervised removal of background noise from scRNA-seq datasets** *bioRxiv* **791699** <https://doi.org/10.1101/791699>
- Hackett B. A., Yasunaga A., Panda D., Tartell M. A., Hopkins K. C., Hensley S. E., Cherry S. (2015) **RNAseq is required for internalization of diverse acid-dependent viruses** *Proc Natl Acad Sci U S A* **112**:7797–7802 <https://doi.org/10.1073/pnas.1424098112>
- Hafemeister C., Satija R. (2019) **Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression** *Genome Biol* **20** <https://doi.org/10.1186/s13059-019-1874-1>
- He Z., Maynard A., Jain A., Gerber T., Petri R., Lin H. C., Treutlein B. (2022) **Lineage recording in human cerebral organoids** *Nat Methods* **19**:90–99 <https://doi.org/10.1038/s41592-021-01344-8>
- Holmgren A. M., Miller K. D., Cavanaugh S. E., Rall G. F. (2015) **Bst2/Tetherin Is Induced in Neurons by Type I Interferon and Viral Infection but Is Dispensable for Protection against Neurotropic Viral Challenge** *J Virol* **89**:11011–11018 <https://doi.org/10.1128/JVI.01745-15>
- Keskinen P., Ronni T., Matikainen S., Lehtonen A., Julkunen I. (1997) **Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells** *Immunology* **91**:421–429 <https://doi.org/10.1046/j.1365-2567.1997.00258.x>
- Korones S. B. (1965) **Bacterial Infection of the Neonate** *GP* **32**:89–100
- Lazar M., Perelygina L., Martinez R., Greer P., Paddock C. D., Peltecu G., Zaki S. R. (2016) **Immunolocalization and Distribution of Rubella Antigen in Fatal Congenital Rubella Syndrome** *EBioMedicine* **3**:86–92 <https://doi.org/10.1016/j.ebiom.2015.11.050>
- McInnes Leland, Healy John, Saul Nathaniel, Großberger L. (2018) **UMAP: Uniform Manifold Approximation and Projection** *Journal of Open Source Software* **3** <https://doi.org/10.21105/joss.00861>
- Lum F. M., Low D. K., Fan Y., Tan J. J., Lee B., Chan J. K., Ng L. F. (2017) **Zika Virus Infects Human Fetal Brain Microglia and Induces Inflammation** *Clin Infect Dis* **64**:914–920 <https://doi.org/10.1093/cid/ciw878>
- Mastromarino P., Cioe L., Rieti S., Orsi N. (1990) **Role of membrane phospholipids and glycolipids in the Vero cell surface receptor for rubella virus** *Med Microbiol Immunol* **179**:105–114 <https://doi.org/10.1007/BF00198531>
- McGinnis C. S., Patterson D. M., Winkler J., Conrad D. N., Hein M. Y., Srivastava V., Gartner Z. J. (2019) **MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices** *Nat Methods* **16**:619–626 <https://doi.org/10.1038/s41592-019-0433-8>

- McQuin C., Goodman A., Chernyshev V., Kametsky L., Cimini B. A., Karhohs K. W., Carpenter A. E. (2018) **CellProfiler 3.0: Next-generation image processing for biology** *PLoS Biol* **16** <https://doi.org/10.1371/journal.pbio.2005970>
- Menassa D. A., Muntslag T. A. O., Martin-Estebane M., Barry-Carroll L., Chapman M. A., Adorjan I., Gomez-Nicola D. (2022) **The spatiotemporal dynamics of microglia across the human lifespan** *Dev Cell* <https://doi.org/10.1016/j.devcel.2022.07.015>
- Menassa D. A., Muntslag T. A. O., Martin-Estebané M., Barry-Carroll L., Chapman M. A., Adorjan I., Gomez-Nicola D. (2021) **Spatiotemporal dynamics of human microglia are linked with brain developmental processes across the lifespan** *bioRxiv* <https://doi.org/10.1101/2021.08.07.455365>
- Monif G. R., Avery G. B., Korones S. B., Sever J. L. (1965) **Postmortem Isolation of Rubella Virus from Three Children with Rubella-Syndrome Defects** *Lancet* **1**:723–724 [https://doi.org/10.1016/s0140-6736\(65\)92084-2](https://doi.org/10.1016/s0140-6736(65)92084-2)
- Munro N. D., Sheppard S., Smithells R. W., Holzel H., Jones G. (1987) **Temporal relations between maternal rubella and congenital defects** *Lancet* **2**:201–204 [https://doi.org/10.1016/s0140-6736\(87\)90775-6](https://doi.org/10.1016/s0140-6736(87)90775-6)
- Nguyen T. V., Pham V. H., Abe K. (2015) **Pathogenesis of Congenital Rubella Virus Infection in Human Fetuses: Viral Infection in the Ciliary Body Could Play an Important Role in Cataractogenesis** *EBioMedicine* **2**:59–63 <https://doi.org/10.1016/j.ebiom.2014.10.021>
- Nowakowski T. J., Bhaduri A., Pollen A. A., Alvarado B., Mostajo-Radji M. A., Di Lullo E., Kriegstein A. R. (2017) **Spatiotemporal gene expression trajectories reveal developmental hierarchies of the human cortex** *Science* **358**:1318–1323 <https://doi.org/10.1126/science.aap8809>
- Otsuki N., Sakata M., Saito K., Okamoto K., Mori Y., Hanada K., Takeda M. (2018) **Both Sphingomyelin and Cholesterol in the Host Cell Membrane Are Essential for Rubella Virus Entry** *J Virol* **92** <https://doi.org/10.1128/JVI.01130-17>
- Pasca A. M., Sloan S. A., Clarke L. E., Tian Y., Makinson C. D., Huber N., Pasca S. P. (2015) **Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture** *Nat Methods* **12**:671–678 <https://doi.org/10.1038/nmeth.3415>
- Perelygina L., Faisthalab R., Abernathy E., Chen M. H., Hao L., Bercovitch L., Sullivan K. E. (2021) **Rubella Virus Infected Macrophages and Neutrophils Define Patterns of Granulomatous Inflammation in Inborn and Acquired Errors of Immunity** *Front Immunol* **12** <https://doi.org/10.3389/fimmu.2021.796065>
- Plotkin S. A. (2021) **Rubella Eradication: Not Yet Accomplished, but Entirely Feasible** *J Infect Dis* **224**:S360–S366 <https://doi.org/10.1093/infdis/jiaa530>
- Popova G., Soliman S. S., Kim C. N., Keefe M. G., Hennick K. M., Jain S., Nowakowski T. J. (2021) **Human microglia states are conserved across experimental models and regulate neural stem cell responses in chimeric organoids** *Cell Stem Cell* **28**:2153–2166 <https://doi.org/10.1016/j.stem.2021.08.015>

- Retallack H., Di Lullo E., Arias C., Knopp K. A., Laurie M. T., Sandoval-Espinosa C., DeRisi J. L. (2016) **Zika virus cell tropism in the developing human brain and inhibition by azithromycin** *Proc Natl Acad Sci U S A* **113**:14408–14413 <https://doi.org/10.1073/pnas.1618029113>
- Rock R. B., Gekker G., Hu S., Sheng W. S., Cheeran M., Lokensgard J. R., Peterson P. K. (2004) **Role of microglia in central nervous system infections** *Clin Microbiol Rev* **17**:942–964 <https://doi.org/10.1128/CMR.17.4.942-964.2004>
- Rorke L. B., Spiro A. J. (1967) **Cerebral lesions in congenital rubella syndrome** *J Pediatr* **70**:243–255 [https://doi.org/10.1016/s0022-3476\(67\)80419-0](https://doi.org/10.1016/s0022-3476(67)80419-0)
- Schanze I., Bunt J., Lim J. W. C., Schanze D., Dean R. J., Alders M., Richards L. J. (2018) **NFIB Haploinsufficiency Is Associated with Intellectual Disability and Macrocephaly** *Am J Hum Genet* **103**:752–768 <https://doi.org/10.1016/j.ajhg.2018.10.006>
- Steele-Perkins G., Plachez C., Butz K. G., Yang G., Bachurski C. J., Kinsman S. L., Gronostajski R. M. (2005) **The transcription factor gene Nfib is essential for both lung maturation and brain development** *Mol Cell Biol* **25**:685–698 <https://doi.org/10.1128/MCB.25.2.685-698.2005>
- Sugishita Y., Akiba T., Sumitomo M., Hayata N., Hasegawa M., Tsunoda T., Tahara N. (2016) **Shedding of Rubella Virus among Infants with Congenital Rubella Syndrome Born in Tokyo, Japan, 2013-2014** *Jpn J Infect Dis* **69**:418–423 <https://doi.org/10.7883/yoken.JJID.2015.316>
- Tchieu J., Calder E. L., Guttikonda S. R., Gutzwiller E. M., Aromolaran K. A., Steinbeck J. A., Studer L. (2019) **NFIA is a gliogenic switch enabling rapid derivation of functional human astrocytes from pluripotent stem cells** *Nat Biotechnol* **37**:267–275 <https://doi.org/10.1038/s41587-019-0035-0>
- Traag V. A., Waltman L., van Eck N. J. (2019) **From Louvain to Leiden: guaranteeing well-connected communities** *Sci Rep* **9** <https://doi.org/10.1038/s41598-019-41695-z>
- van der Logt J. T., van Loon A. M., van der Veen J. (1980) **Replication of rubella virus in human mononuclear blood cells** *Infect Immun* **27**:309–314 <https://doi.org/10.1128/iai.27.2.309-314.1980>
- Vynnycky E., Adams E. J., Cutts F. T., Reef S. E., Navar A. M., Simons E., Dabbagh A. J. (2016) **Using Seroprevalence and Immunisation Coverage Data to Estimate the Global Burden of Congenital Rubella Syndrome, 1996-2010: A Systematic Review** *PLoS One* **11** <https://doi.org/10.1371/journal.pone.0149160>
- Warre-Cornish K., Perfect L., Nagy R., Duarte R. R. R., Reid M. J., Raval P., Price J. (2020) **Interferon-gamma signaling in human iPSC-derived neurons recapitulates neurodevelopmental disorder phenotypes** *Sci Adv* **6** <https://doi.org/10.1126/sciadv.aay9506>
- World Health Organization, W (2020) **Rubella vaccines: WHO position paper** *Weekly Epidemiological Record* **95**:306–324
- World Health Organization, W (2022) **World Health Organization, W. (2022). Immunization dashboard.** doi:<https://immunizationdata.who.int/pages/incidence/crs.html?CODE=Global&YEAR=>

Article and author information

Galina Popova

Department of Anatomy, University of California San Francisco, San Francisco, CA, USA,
Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA, Eli and
Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of
California, San Francisco, CA, USA
ORCID iD: [0000-0001-8249-219X](https://orcid.org/0000-0001-8249-219X)

Hanna Retallack

Department of Biochemistry and Biophysics, University of California San Francisco, San
Francisco, CA, USA
ORCID iD: [0000-0003-0533-9102](https://orcid.org/0000-0003-0533-9102)

Chang N. Kim

Department of Anatomy, University of California San Francisco, San Francisco, CA, USA,
Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA, Eli and
Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of
California, San Francisco, CA, USA

David Shin

Department of Anatomy, University of California San Francisco, San Francisco, CA, USA,
Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA, Eli and
Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of
California, San Francisco, CA, USA

Albert Wang

Department of Anatomy, University of California San Francisco, San Francisco, CA, USA

Joseph DeRisi

Department of Biochemistry and Biophysics, University of California San Francisco, San
Francisco, CA, USA, Chan Zuckerberg Biohub, San Francisco, CA, USA
For correspondence: joe@derisilab.ucsf.edu
ORCID iD: [0000-0002-4611-9205](https://orcid.org/0000-0002-4611-9205)

Tomasz J. Nowakowski

Department of Anatomy, University of California San Francisco, San Francisco, CA, USA,
Department of Psychiatry, University of California San Francisco, San Francisco, CA, USA, Eli and
Edythe Broad Center for Regeneration Medicine and Stem Cell Research, University of
California, San Francisco, CA, USA, Weill Institute for Neurosciences, University of California San
Francisco, San Francisco, CA, USA, Chan Zuckerberg Biohub, San Francisco, CA, USA
For correspondence: tomasz.nowakowski@ucsf.edu

Copyright

© 2023, Popova et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use and redistribution provided that the original author and
source are credited.

Editors

Reviewing Editor

Joseph Gleeson

University of California, San Diego, La Jolla, United States of America

Senior Editor

Sara Sawyer

University of Colorado Boulder, Boulder, United States of America

Reviewer #1 (Public Review):

The authors sought to address the longstanding question of which cell types are infected during congenital or perinatal rubella virus infection. They used brain slice and organoid-microglia experimental models to demonstrate that the main cell types targeted by rubella virus are microglia. It does not appear that microglia support rubella virus production in this experimental system, though future studies would be needed to address this more thoroughly. The authors further show that infection results in augmented interferon responses in neighboring neuronal cells but not in the microglia themselves. The data support the conclusions, with major strengths being the sophisticated primary cell models and single-cell RNA-Seq used to pinpoint microglia as the main cellular targets of rubella virus, and neurons as the bystander targets of immune signaling. This study reveals a new cellular target that will have important implications for basic studies on rubella virus-host interactions and for the potential development of therapies or improved vaccines targeting this virus. As rubella virus is a pathogen of high concern during human pregnancy, this study also has important implications in the field of neonatal infectious diseases.

- <https://doi.org/10.7554/eLife.87696.1.sa1>

Reviewer #2 (Public Review):

In this manuscript by Popova et al., the authors report the pathological impact of Rubella virus (RV) infection on human brain development. In particular, they uncovered a selective tropism of Rubella virus for microglial cells in cultured slices of human developing brain and 2D mixed fetal brain cell culture. Their results suggest that RV infection of microglia relies on the presence of diffusible factors from other cell populations. Moreover, the authors showed that RV infection of human brain organoids supplemented or not with microglia leads to interferon response and dysregulation of gene involved in brain development. This set of data will help understanding the cellular specificity and pathological mechanisms occurring in the developing brain upon RV infection. The data provided are overall of high quality and shed new light on the cellular tropism and the pathomechanisms of RV infection.

- <https://doi.org/10.7554/eLife.87696.1.sa0>